RETINALGENIX TECHNOLOGIES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.5 USD | +12.90% |
|
-.--% | +13.27% |
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 54.35M |
|---|---|---|---|---|---|
| Net income 2022 | -3M | Net income 2023 | -2M | EV / Sales 2022 | - |
| Net Debt 2022 | 0.16 | Net Debt 2023 | 0.51 | EV / Sales 2023 | - |
| P/E ratio 2022 |
-35.8
x | P/E ratio 2023 |
-25.6
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 29.99% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +12.90% | ||
| 3 months | +12.90% | ||
| 6 months | -22.05% | ||
| Current year | +13.27% |
Current year
3.10
3.50
1 year
3.004.49
3 years
3.0020.00
5 years
3.0020.00
10 years
3.0020.00
| Managers | Title | Age | Since |
|---|---|---|---|
Erhan Gunday
FOU | Founder | - | - |
Jerry Katzman
CEO | Chief Executive Officer | 71 | 18-07-31 |
| Director of Finance/CFO | 66 | Nov. 29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jerry Katzman
CEO | Chief Executive Officer | 71 | 18-07-31 |
Herbert L. Gould
BRD | Director/Board Member | 95 | 19-03-31 |
Vinay Mehindru
BRD | Director/Board Member | - | 22-07-25 |
RetinalGenix Technologies Inc. is an ophthalmic research and development company. The Company is focused on creating solutions to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders and to enable the early detection and treatment of multiple systemic diseases through a combination of therapeutic medications and medical device technologies. The Company is focused on preventing vision loss and blindness due to ocular diseases, including diabetic retinopathy and maculopathy, in its first two devices: Retinal Imaging Screening Device and RetinalCam. Retinal Imaging Screening Device is a portable, retinal imaging system providing a wide field of view without requiring pupil dilation. RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real time communication and alerting system for physicians available 24/7. The Company is also engaged in the development of its product candidates: RTG-2023 and RTG-2024.
| 1st Jan change | Capi. | |
|---|---|---|
| +13.27% | 62.25M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- RTGN Stock
